Brind.
  1. Klotho Neurosciences received Orphan Drug Designation from the FDA for its KLTO-202 gene therapy, targeting ALS, Alzheimer's, and Parkinson's.

Klotho Neurosciences will use AAVnerGene's platform for manufacturing its gene therapy.

2 reports, 1 independent Updated Aug 12
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Klotho Neurosciences will use AAVnerGene's platform for manufacturing its gene therapy.

Keep exploring

Part of

Klotho Neurosciences received Orphan Drug Designation from the FDA for its KLTO-202 gene therapy, targeting ALS, Alzheimer's, and Parkinson's. All 1 developments

Coverage

Newest first; wire copies grouped
  • PR NewswireKlotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Na
  • PR NewswireKlotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets NEW YORK, July 22, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), announced that it is p